Search clinical trials for: BI 1744 CL

Total 1554 results

Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks Treatment With Inhaled BI 1744 CL in Japanese Patients With COPD

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

BI 1744 CL in Patients With Severe Renal Impairment in Comparison to Subjects With Normal Renal Function

Healthy
Boehringer Ingelheim

Completed

Single Dose of BI 1744 CL in Patients With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function

Liver Diseases | Healthy
Boehringer Ingelheim

Completed

Investigation of the Metabolism and Pharmacokinetics of [14C]BI 1744 CL and [14C]BI 1744 CL Administered as an Oral Solution in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics and Safety of BI 1744 CL Plus Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Boehringer Ingelheim

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Doses of BI 187004 CL

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 11054 CL Administered With the Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Inhaled BI 1744 CL in Patients With Asthma

Asthma

United States, Canada, France, Germany
Boehringer Ingelheim

Completed

BI 1744 CL With Respimat Once Daily Versus Twice Daily in COPD

Pulmonary Disease, Chronic Obstructive

Belgium, Netherlands
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

Single Rising Peroral Doses of BI 1744 CL in Healthy Volunteers

Healthy
Boehringer Ingelheim

Completed

Multiple Rising Inhalative Doses of BI 1744 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Via Respimat® Inhaled BI 1744 CL Compared to Moxifloxacin and Placebo in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study to Assess Safety, Tolerability and Pharmacokinetics of Single Rising Inhaled Doses of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

Influence of a Standardised High Fat Breakfast on the Bioavailability of BI 14332 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BI 1744 CL in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

A Study of the Safety and Efficacy of 4 Doses of BI 1744 CL Delivered Via the Respimat in Patients With Asthma.

Asthma

Austria, Germany, Poland, Romania, Slovakia, Slovenia
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry I

Pulmonary Disease, Chronic Obstructive

Australia, Austria, Canada, France, Germany
Boehringer Ingelheim

Completed

Effect of Treatment BI 1744 CL (5 and 10 mcg) Versus Placebo on Exercise Endurance Time During Constant Work Rate Cycle Ergometry II

Pulmonary Disease, Chronic Obstructive

Austria, Belgium, Canada, Germany, Russian Federation
Boehringer Ingelheim

Completed

Study to Investigate Safety and Tolerability of BI 1744 CL in Free Dose Combination With Tiotropium Bromide Both Administered by Respimat® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Characterisation of 24-hour FEV1-time Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

United States
Boehringer Ingelheim

Completed

Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Belgium, Canada, Germany
HeNan Sincere Biotech Co., Ltd

Completed

A Study of CL-197 Capsules in Healthy Participants

HIV-1

China
Boehringer Ingelheim

Completed

Determining Optimal Free Dose Combination of Tiotropium Bromide and BI 1744 CL in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

Canada, Germany, Netherlands, Sweden
Boehringer Ingelheim

Completed

Combination of Orally Inhaled BI1744CL/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease ( COPD)

Pulmonary Disease, Chronic Obstructive

United States, Canada, Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Inhalative Doses of BI 1744 CL in Fixed Dose Combination With Tiotropium Bromide in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Investigation of Pharmacokinetics of BIBX 245 CL and Safety in Healthy Subjects

Healthy
Boehringer Ingelheim

Completed

12 / 48 wk Pivotal PFT vs PBO in COPD II

Pulmonary Disease, Chronic Obstructive

United States, China, Germany, Taiwan
Contour Research

Completed

Examination of Circumferential Reduction

Overweight or Obesity

United States
LG Chem

Active, not recruiting

A Phase I Clinical Trial to Investigate the Safety, Tolerability, and Pharmacokinetic Characteristics of TT-01025-CL in Healthy Subjects

Healthy

United States
Federico II University

Withdrawn

Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth

Preterm Birth

Italy
HeartWorks, Inc.

Recruiting

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Congenital Heart Disease | Univentricular Heart | Heart Failure NYHA Class III | Heart Failure NYHA Class IV

United States
University of Vermont

Completed

Role of Magnesium Supplementation in the Treatment of Depression

Depression

United States
Medecins Sans Frontieres, Netherlands

Terminated

Effectiveness, Safety and Feasibility of HECT-CL, in Quetta, Pakistan (HECT-CL)

Cutaneous Leishmaniases

Pakistan
Chugai Pharmaceutical

Completed

Clinical Study of R744 to Peritoneal Dialysis Patients

Peritoneal Dialysis Patients

Japan
Boehringer Ingelheim

Completed

Single Increasing Doses of BIII 890 CL in Healthy Young Male Volunteers and in Healthy Elderly Male and Female Volunteers

Healthy
Boehringer Ingelheim

Terminated

Safety, Pharmacodynamics, and Pharmacokinetics After Multiple Different Oral Doses of BIIB 722 CL Tablets in Healthy Volunteers

Healthy
InQpharm Group

Completed

IQP-CL-101 in IBS Management

Irritable Bowel Syndrome

Germany
Boehringer Ingelheim

Completed

Study to Determine Pharmacodynamic Effects and Pharmacokinetics of KUC 7483 CL in Patients With Spinal Cord Injury and Neurogenic Detrusor Overactivity

Spinal Cord Injuries
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of KUC 7483 CL Tablets in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Increasing Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Single Dose Followed by Maintenance Dose Tolerance Study of BIIR 561 CL in Healthy Elderly Male and Female Volunteers

Healthy
Octapharma

Completed

Study to Investigate Immunogenicity, Efficacy and Safety of Treatment With Human-cl rhFVIII

Severe Hemophilia A

United States, France, Canada, United Kingdom, India, Georgia, Moldova, Republic of, Poland, Ukraine
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of Oral BIBP 5371 CL in Healthy Male and Female Volunteers

Healthy
Avidity Biosciences, Inc.

Enrolling by invitation

Ph2 Open-label Study of AOC 1044 in Duchenne Muscular Dystrophy Participants With Mutations Amenable to Exon44 Skipping (EXPLORE44OLE)

Duchenne Muscular Dystrophy | DMD | Exon 44 | Duchenne

United States
Boehringer Ingelheim

Recruiting

A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab

Melanoma | Non-small Cell Lung Cancer (NSCLC) | Carcinoma, Squamous Cell of Head and Neck (HNSCC)

Netherlands

3

Subscribe